COVID vaccination associated immunological cutaneous reactions
British Journal of Dermatology
; 186(6):e250, 2022.
Article
in English
| EMBASE | ID: covidwho-1956695
ABSTRACT
While our knowledge about the short-term side-effects of COVID-19 vaccination in adults has rapidly evolved, data about the long-term systemic side-effects and potential new onset autoimmune disorders has been limited. Here we present a case series of patients with new onset autoimmune skin conditions between 10 days and 4 weeks post mRNA COVID-19 vaccination and discuss the underlying pathophysiological changes contributing to these side-effects. Exclusions included any patients who have previously tested positive for COVID-19 or had COVID-19 symptoms. Our cases include new onset discoid lupus, localized cutaneous lupus, dermatomyositis, linear IgA bullous disease, pemphigus vulgaris, bullous pemphigoid, lichen planus pemphigoides, erosive lichen planus, psoriasis and vitiligo. In addition, we are reporting significant flare-up of pre-existing autoimmune skin conditions after a long period of remission. These include three cases of psoriasis, two cases of systemic lupus, one pemphigus vulgaris koebnerizing within a previous shingles site, and a case of pyoderma gangrenosum flare. The BNT162b2 vaccine is a potent activator of the T- and B-cell pathways. The production of interleukin (IL)-17 and IL- 21 seems to play an important role in vaccine-induced immunological protection, which is also linked to germinal centre activation linked to autoimmune disorders. This report improves our knowledge regarding some rarer potential sideeffects associated with these new vaccines and highlights the importance of further studies.
endogenous compound; interleukin 17; interleukin 21; messenger RNA; tozinameran; adult; autoimmune disease; B lymphocyte; bullous pemphigoid; case report; case study; clinical article; conference abstract; coronavirus disease 2019; dermatomyositis; discoid lupus erythematosus; disease exacerbation; female; gene expression; germinal center; herpes zoster; human; human cell; lichen planus; linear iga bullous dermatosis; male; pemphigus vulgaris; psoriasis; pyoderma gangrenosum; remission; side effect; skin disease; skin manifestation; systemic lupus erythematosus; vaccination; vitiligo
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
British Journal of Dermatology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS